| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kaiyan Yang, Xinyu Qin, Huiyang Wang, Wenbo Zho. Exploring genetic causal relationship between antidepressants use and congenital malformations. Reproductive toxicology (Elmsford, N.Y.). 2024-10-19. PMID:39426691. |
the exposure datasets included the use of antidepressants, responses to selective serotonin reuptake inhibitors (ssris), and the use of four ssris-related antidepressants: fluoxetine, citalopram, paroxetine, and sertraline. |
2024-10-19 |
2024-10-22 |
Not clear |
| Veronika Vachalova, Fiona Kumnova, Tetiana Synova, Kasin Yadunandam Anandam, Cilia Abad, Rona Karahoda, Frantisek Stau. Metformin inhibits OCT3-mediated serotonin transport in the placenta. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 179. 2024-09-07. PMID:39243433. |
in primary trophoblasts, paroxetine exhibited the strongest inhibition of serotonin uptake, followed by decynium-22. |
2024-09-07 |
2024-09-10 |
human |
| Luke R Cavanah, Jessica L Goldhirsh, Leighton Y Huey, Brian J Pipe. National patterns of paroxetine use among US Medicare patients from 2015-2020. Frontiers in psychiatry. vol 15. 2024-07-26. PMID:39050917. |
paroxetine is an older "selective" serotonin reuptake inhibitor (ssri) that is notable for its lack of selectivity, resulting in an anticholinergic adverse-effect profile, especially among older adults (65+). |
2024-07-26 |
2024-07-28 |
Not clear |
| Andrew Reuter, Andrew Nerland, Deborah Pritchett, Maria Skore. Antidepressant Medication Use During Lactation: A Review for Providers. South Dakota medicine : the journal of the South Dakota State Medical Association. vol 77. issue 4. 2024-07-11. PMID:38991162. |
the selective serotonin reuptake inhibitors (ssris) sertraline and paroxetine are present in low levels and are considered preferred agents. |
2024-07-11 |
2024-07-14 |
Not clear |
| Toczyska Klaudia, Haq Naila, Lyu Zekun, Bewick Gavin, Zhao Min, Rosa Hannah, Starikova Jessica, Liu Bo, Shanta Jean Persau. The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta-cell mass and function in vitro. Diabetes, obesity & metabolism. 2024-06-18. PMID:38888050. |
the selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta-cell mass and function in vitro. |
2024-06-18 |
2024-06-21 |
Not clear |
| Toczyska Klaudia, Haq Naila, Lyu Zekun, Bewick Gavin, Zhao Min, Rosa Hannah, Starikova Jessica, Liu Bo, Shanta Jean Persau. The selective serotonin reuptake inhibitors, sertraline and paroxetine, improve islet beta-cell mass and function in vitro. Diabetes, obesity & metabolism. 2024-06-18. PMID:38888050. |
to investigate the effects of the selective serotonin reuptake inhibitors (ssris) sertraline and paroxetine at therapeutically relevant concentrations on beta-cell mass and function. |
2024-06-18 |
2024-06-21 |
Not clear |
| Sujin Jeong, Yoseob Kim, Sanggil Choe, Hyunwook Kang, Hyung Min Kim, Jong Seong Kan. A fatal case of desvenlafaxine and paroxetine poisoning. Journal of pharmaceutical and biomedical analysis. vol 245. 2024-04-23. PMID:38652939. |
desvenlafaxine (o-desmethylvenlafaxine) and paroxetine are antidepressants that inhibit serotonin reuptake. |
2024-04-23 |
2024-04-26 |
Not clear |
| Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Shar. Rebound activation of 5-HT neurons following SSRI discontinuation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-04-12. PMID:38609530. |
here we determined the effect on 5-ht neurochemistry of discontinuation from the ssri paroxetine. |
2024-04-12 |
2024-04-15 |
mouse |
| Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Shar. Rebound activation of 5-HT neurons following SSRI discontinuation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-04-12. PMID:38609530. |
whereas brain tissue levels of 5-ht and/or its metabolite 5-hiaa tended to decrease during continuous paroxetine, levels increased above controls after discontinuation, notably in hippocampus. |
2024-04-12 |
2024-04-15 |
mouse |
| Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Shar. Rebound activation of 5-HT neurons following SSRI discontinuation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-04-12. PMID:38609530. |
in microdialysis experiments continuous paroxetine elevated hippocampal extracellular 5-ht and this effect fell to saline control levels on discontinuation. |
2024-04-12 |
2024-04-15 |
mouse |
| Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Shar. Rebound activation of 5-HT neurons following SSRI discontinuation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-04-12. PMID:38609530. |
however, depolarisation (high potassium)-evoked 5-ht release was reduced by continuous paroxetine but increased above controls post-discontinuation. |
2024-04-12 |
2024-04-15 |
mouse |
| Helen M Collins, L Sophie Gullino, Dersu Ozdemir, Caroline Lazarenco, Yulia Sudarikova, Elizabeth Daly, Fuencisla Pilar Cuéllar, Raquel Pinacho, David M Bannerman, Trevor Shar. Rebound activation of 5-HT neurons following SSRI discontinuation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-04-12. PMID:38609530. |
next, immunohistochemistry experiments found that paroxetine discontinuation increased c-fos expression in midbrain 5-ht (tph2 positive) neurons, adding further evidence for a hyperexcitable 5-ht system. |
2024-04-12 |
2024-04-15 |
mouse |
| Xiang-Ming Cai, Xiao-Yu Sun, Rui Li, Pei-Juan Wang, Jian-Cheng Qi, Yu-Xin Ge, Lei Yan. The hippocampal Salt-Inducible Kinase 2-CREB-Regulated Transcription Co-activator 1 system mediates the antidepressant actions of paroxetine in mice. Behavioural brain research. 2024-03-29. PMID:38552744. |
like fluoxetine, paroxetine is also a widely used selective serotonin (5-ht) reuptake inhibitor (ssri). |
2024-03-29 |
2024-04-01 |
mouse |
| Gemma Mestre-Bach, Marc N Potenz. Current Understanding of Compulsive Sexual Behavior Disorder and Co-occurring Conditions: What Clinicians Should Know about Pharmacological Options. CNS drugs. 2024-03-15. PMID:38485889. |
the main pharmacological approaches to treating csbd have included opioid antagonists (naltrexone and nalmefene), selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine, and sertraline), mood stabilizers (topiramate), tricyclic antidepressants (clomipramine), serotonin antagonist and reuptake inhibitors (nefazodone), and n-acetylcysteine. |
2024-03-15 |
2024-03-17 |
Not clear |
| Qianrui Huang, Mengling Wu, Yamin Pu, Junyou Zhou, Yiqian Zhang, Ru Li, Yong Xia, Yiwen Zhang, Yimei M. Inhibition of TNBC Cell Growth by Paroxetine: Induction of Apoptosis and Blockage of Autophagy Flux. Cancers. vol 16. issue 5. 2024-03-13. PMID:38473249. |
paroxetine (px), a selective serotonin reuptake inhibitor typically utilized in the treatment of depression, has demonstrated promise as an agent for combating cancer. |
2024-03-13 |
2024-03-15 |
Not clear |
| Yuhua Jin, Lamei Yu, Yan L. Paroxetine Effect on Nerve Growth Factor, Human Neurotrophin-4, Brain-Derived Neurotrophic Factor Levels in Post-stroke Depression. Molecular neurobiology. 2024-03-05. PMID:38443730. |
for post-stroke depression, paroxetine treatment can effectively improve ngf, nt-4, bdnf, 5-ht, hcy, and ne levels and effectively reduce the degree of neurological damage and depression, which has high clinical application value. |
2024-03-05 |
2024-03-08 |
human |
| Fumiya Inoue, Yuji Okazaki, Toshihisa Ichiba, Kenichiro Kashiwa, Akira Namer. Unexpectedly Prolonged Serotonin Syndrome and Fatal Complications Following a Massive Overdose of Paroxetine Controlled-Release. Cureus. vol 15. issue 12. 2024-01-17. PMID:38229825. |
unexpectedly prolonged serotonin syndrome and fatal complications following a massive overdose of paroxetine controlled-release. |
2024-01-17 |
2024-01-19 |
Not clear |
| Fumiya Inoue, Yuji Okazaki, Toshihisa Ichiba, Kenichiro Kashiwa, Akira Namer. Unexpectedly Prolonged Serotonin Syndrome and Fatal Complications Following a Massive Overdose of Paroxetine Controlled-Release. Cureus. vol 15. issue 12. 2024-01-17. PMID:38229825. |
we describe a fatal case of severe serotonin syndrome and acute respiratory distress syndrome (ards) following an overdose of controlled-release paroxetine. |
2024-01-17 |
2024-01-19 |
Not clear |
| Letícia Rampazzo da Gama Viveiro, Amanda Rodrigues Rehem, Evelyn Luzia De Souza Santos, Paulo Henrique Fonseca do Carmo, Juliana Campos Junqueira, Liliana Scorzon. In vitro effects of selective serotonin reuptake inhibitors on Cryptococcus gattii Capsule and biofilm. Pathogens and disease. 2024-01-11. PMID:38204138. |
this study aimed to validate the efficacy of selective serotonin reuptake inhibitors (ssri) fluoxetine hydrochloride (flh) and paroxetine hydrochloride (pah) in vitro against c. gattii. |
2024-01-11 |
2024-01-13 |
Not clear |
| Mingfeng Fan, Laian Li, Xiangjun Xu, Cong Zhou, Peng Wang, Wanbin Yin, Wenju Pei, Shuai Wan. Psychological status of patients with functional anorectal pain and treatment efficacy of paroxetine in alleviating the symptoms: a retrospective study. Scientific reports. vol 13. issue 1. 2023-10-21. PMID:37865675. |
paroxetine, a typical serotonin reuptake inhibitor (ssri), was able to alleviate depression, anxiety, and pain symptoms in fap, which might have clinical application prospects. |
2023-10-21 |
2023-11-08 |
Not clear |